Cargando…

Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin

Coronary heart disease (CHD) is the leading cause of death worldwide. The efficacy and safety of statins in primary and secondary prevention of CHD is confirmed in several large studies, and rosuvastatin is the latest statin on market. We review the published literature on rosuvastatin in Chinese pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhen, Ge, Junbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861292/ https://www.ncbi.nlm.nih.gov/pubmed/24353409 http://dx.doi.org/10.2147/CIA.S41356

Ejemplares similares

Factors of Compliance in Patients with Hypercholesterolemia Using Rosuvastatin in Primary Care
por: Kim, Hye Young, et al.
Publicado: (2012)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Hoping rosuvastatin for primary prevention of cardiovascular events, are all statins similar and are we ready for statinizing the globe?
por: Kumar, Arun H. S.
Publicado: (2016)

Effect of fixed‐dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS‐ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)
por: Kim, Kyung‐Jin, et al.
Publicado: (2016)

Higher Responsiveness to Rosuvastatin in Polygenic versus Monogenic Hypercholesterolemia: A Propensity Score Analysis
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
por: Long, Sydney B, et al.
Publicado: (2011)

Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes
por: Torimoto, Keiichi, et al.
Publicado: (2013)

Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia
por: Wagner, Jonathan B., et al.
Publicado: (2020)

Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
por: Perez-Calahorra, Sofía, et al.
Publicado: (2019)

Phytosterols in the Treatment of Hypercholesterolemia and Prevention of Cardiovascular Diseases
por: Cabral, Carlos Eduardo, et al.
Publicado: (2017)

Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia
por: Park, Jong-Seon, et al.
Publicado: (2010)

Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia
por: Khoury, Etienne, et al.
Publicado: (2020)

Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE)
por: Mehta, Ashwani, et al.
Publicado: (2022)

Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
por: Clearfield, Michael B, et al.
Publicado: (2006)

Lifestyle, Cardiovascular Drugs and Risk Factors in Younger and Elder Adults: The PEP Family Heart Study
por: Schwandt, Peter, et al.
Publicado: (2010)

Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
por: Stoll, Felicitas, et al.
Publicado: (2022)

The Role of Bifidobacteria in Predictive and Preventive Medicine: A Focus on Eczema and Hypercholesterolemia
por: Marras, Luisa, et al.
Publicado: (2021)

Hyperuricemia is associated with more cardiometabolic risk factors in hypertensive younger Chinese adults than in elderly
por: Su, Xiaofeng, et al.
Publicado: (2023)

Effects of rosuvastatin/ezetimibe on senescence of CD8+ T-cell in type 2 diabetic patients with hypercholesterolemia: A study protocol
por: Ju, Sang Hyeon, et al.
Publicado: (2022)

Efficacy and safety of rosuvastatin in the management of dyslipidemia
por: Rubba, Paolo, et al.
Publicado: (2009)

Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID‐19 pandemic
por: Huang, Helen, et al.
Publicado: (2023)

Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective
por: Kones, Richard
Publicado: (2010)

An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention
por: Gallo, Giovanna, et al.
Publicado: (2023)

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
por: Gandhi, Sanjay K, et al.
Publicado: (2012)

Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention
por: Koutsogianni, Amalia Despoina, et al.
Publicado: (2022)

Dilemmas in the Management of Osteoporosis in Younger Adults
por: Herath, Madhuni, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis
por: Yang, Han, et al.
Publicado: (2020)

Comment: Prevalence of Hypercholesterolemia and Awareness of Risk Factors, Prevention and Management Among Adults [Letter]
por: Nugroho, Heru Santoso Wahito, et al.
Publicado: (2023)

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
por: Luvai, Ahai, et al.
Publicado: (2012)

Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2020)

Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention
por: Chehrevar, Morteza, et al.
Publicado: (2022)

Polygenic Hypercholesterolemia and Cardiovascular Disease Risk
por: Sharifi, Mahtab, et al.
Publicado: (2019)

Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
por: Dai, Yuxiang, et al.
Publicado: (2012)

Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients at Cardiovascular Risk
por: Yang, Yujin, et al.
Publicado: (2021)

Hypercholesterolemia and its correlates in Taiwanese elderly people.
por: Lin, C. C., et al.
Publicado: (1999)

The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial
por: Obońska, Karolina, et al.
Publicado: (2017)

Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices
por: Thongtang, Nuntakorn, et al.
Publicado: (2022)

HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures
por: Buuren, Frank van, et al.
Publicado: (2012)

Heterozygous Familial Hypercholesterolemia With APOE Haplotype: A Prospective Harbinger of a Catastrophic Cardiovascular Event
por: Lasam, Glenmore, et al.
Publicado: (2017)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_on8j1t9gloap87uj5896r15qno